Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses roadblocks to cancer screenings first thrown up by the COVID-19 pandemic in 2020 and that continue to reverberate today.
Although numbers of cancer screenings are improving, they remain down, and these screenings are delayed because the issue is multifaceted: There is diminished capacity to handle screening requests, staffing issues, and social distancing, so that even people who are ready and want to get screened still are delayed in doing so, noted Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, when addressing roadblocks to cancer screenings first thrown up by the COVID-19 pandemic that continue still.
Transcript
Is there any sign that cancer screenings are returning to prepandemic levels?
Cancer screening has been substantially impacted by the pandemic. We know that, as we published early in 2020, that in 2020, rates were dramatically down across the board for breast, colon, prostate, and lung cancer screenings. We have seen levels improve, but they have not yet returned to normal. In fact, so much so that there are delays in even people that want to get screening getting screened. There’s a multifaceted issue that people are still delaying screenings and there is diminished capacity in each place that does cancer screening, to some degree because of social distancing, to some degree because of staffing. And they just can’t flex to accommodate all the people that have delayed, even if they were all ready to go get screened. No, things have not returned to normal, it still does remain a problem, but it’s much better than we saw in 2020.
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
January 15th 2025The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Designing Care for the Underserved Creates Higher-Value Health Solutions
January 12th 2025In the second half of our interview with Brita Roy, MD, MPH, MHS, NYU Grossman School of Medicine, she discusses effective engagement of minoritized populations in discussion of medical mistrust.
Read More
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
January 15th 2025The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Designing Care for the Underserved Creates Higher-Value Health Solutions
January 12th 2025In the second half of our interview with Brita Roy, MD, MPH, MHS, NYU Grossman School of Medicine, she discusses effective engagement of minoritized populations in discussion of medical mistrust.
Read More
2 Commerce Drive
Cranbury, NJ 08512